The focus of the industry is living organisms, and the highly regulated standards make it a unique concern for business executives. These attributes make the industry a natural https://genotec-frankfurt.de/ incubator for innovation, leading to some major breakthroughs that have improved agricultural yields, created biofuels and led to life-saving pharmaceutical products.
When it comes to strategies for generating revenue biotech start-ups have numerous options. The majority opt for a technology partnership or an asset creation-and-out-licensing strategy. Technology partnering can bring more revenue and reduce risk to the financials, whereas asset creation and outlicensing strategies can generate significantly greater returns. An increasing number of biotechs at the research stage use in a hybrid approach that combines both approaches.
If you choose to go with a product-oriented strategy are more likely to achieve commercial success in the event that they manage to bring their pipelines to the right place, and then find a major pharmaceutical partner or an investor with a large sum of money. It can be a costly proposition. It is important to consider the balance between opportunistic strategies in leveraging assets from outside and make best scientific decisions for the development of home-grown products.
The “platform” model is a second option to generate revenue. It is less costly than product-oriented development, but is a risky option. In this model biotechs create and own their platform technology before partnering up with big pharma to create a range of drug discovery projects that target specific diseases (i.e. disease x is a biological condition that causes). This is the method Advinus Therapeutics and a few others have taken.